SG11201402351WA - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy - Google Patents
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapyInfo
- Publication number
- SG11201402351WA SG11201402351WA SG11201402351WA SG11201402351WA SG11201402351WA SG 11201402351W A SG11201402351W A SG 11201402351WA SG 11201402351W A SG11201402351W A SG 11201402351WA SG 11201402351W A SG11201402351W A SG 11201402351WA SG 11201402351W A SG11201402351W A SG 11201402351WA
- Authority
- SG
- Singapore
- Prior art keywords
- adm
- antibody
- adrenomedullin
- scaffold
- therapy
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189448 | 2011-11-16 | ||
| EP12160018 | 2012-03-16 | ||
| PCT/EP2012/072931 WO2013072512A1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402351WA true SG11201402351WA (en) | 2014-06-27 |
Family
ID=48087103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402351WA SG11201402351WA (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2594588B1 (ru) |
| JP (1) | JP6321545B2 (ru) |
| KR (3) | KR102047443B1 (ru) |
| CN (4) | CN110054690B (ru) |
| AU (1) | AU2012338732B2 (ru) |
| BR (2) | BR112014011670B1 (ru) |
| CA (1) | CA2856141C (ru) |
| DK (1) | DK2594588T3 (ru) |
| ES (1) | ES2494191T3 (ru) |
| HK (1) | HK1202127A1 (ru) |
| IL (2) | IL283215B2 (ru) |
| MX (1) | MX355482B (ru) |
| PL (1) | PL2594588T3 (ru) |
| PT (1) | PT2594588E (ru) |
| RU (1) | RU2662671C2 (ru) |
| SG (1) | SG11201402351WA (ru) |
| WO (1) | WO2013072512A1 (ru) |
| ZA (1) | ZA201403548B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2594588T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| WO2017089474A1 (en) * | 2015-11-27 | 2017-06-01 | Brahms Gmbh | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT |
| ES2948446T3 (es) * | 2016-07-08 | 2023-09-12 | Sphingotec Gmbh | Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| RU2762059C2 (ru) * | 2016-12-16 | 2021-12-15 | Адреномед Аг | Антитело против адреномедуллина (adm), или фрагмент анти-adm антитела, или анти-adm не-ig каркас для применения при вмешательстве и терапии гиперемии у пациента |
| EP3604538A4 (en) * | 2017-03-29 | 2020-12-30 | University of Miyazaki | LONG-ACTING ADRENOMEDULLINE DERIVATIVE |
| CN111511390A (zh) * | 2017-09-25 | 2020-08-07 | 艾德里诺医药公司 | 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 |
| US20220268761A1 (en) | 2017-10-18 | 2022-08-25 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| KR20200135947A (ko) * | 2018-02-08 | 2020-12-04 | 스핑고텍 게엠베하 | 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 |
| EP4021571A1 (en) | 2019-08-30 | 2022-07-06 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock |
| WO2021170838A1 (en) | 2020-02-27 | 2021-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| JP2023515985A (ja) | 2020-02-27 | 2023-04-17 | アドレノメト アクチェンゲゼルシャフト | ショック状態の患者の治療において使用するための抗アドレノメデュリン（ａｄｍ）結合剤 |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| TW202413415A (zh) * | 2022-07-20 | 2024-04-01 | 大陸商上海濟煜醫藥科技有限公司 | 抗腎上腺髓質素非中和抗體、其製備方法及用途 |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU774725B2 (en) * | 1999-09-10 | 2004-07-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Determination of adrenomedullin-binding proteins |
| US20040023334A1 (en) | 2001-08-30 | 2004-02-05 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| JP2007523844A (ja) | 2003-04-25 | 2007-08-23 | ジェノバ・リミテッド | 心臓血管障害において減少する分泌ポリペプチド種 |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| CA2477867A1 (en) * | 2004-09-17 | 2006-03-17 | Oncorex, Inc. | Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| CN101165067B (zh) * | 2006-10-19 | 2011-04-20 | 四川大学华西医院 | 肾上腺髓质素(27-52)的固相合成方法 |
| WO2009077175A1 (en) | 2007-12-19 | 2009-06-25 | Affibody Ab | Polypeptide derived from protein a and able to bind pdgf |
| JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質 |
| NZ598351A (en) | 2009-08-27 | 2014-08-29 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
| WO2011073209A1 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
| NZ603562A (en) | 2010-06-08 | 2014-07-25 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| PL2594588T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
-
2012
- 2012-11-16 PL PL12193121T patent/PL2594588T3/pl unknown
- 2012-11-16 BR BR112014011670-9A patent/BR112014011670B1/pt active IP Right Grant
- 2012-11-16 AU AU2012338732A patent/AU2012338732B2/en active Active
- 2012-11-16 IL IL283215A patent/IL283215B2/en unknown
- 2012-11-16 SG SG11201402351WA patent/SG11201402351WA/en unknown
- 2012-11-16 BR BR122019027917-9A patent/BR122019027917B1/pt active IP Right Grant
- 2012-11-16 RU RU2014123990A patent/RU2662671C2/ru active
- 2012-11-16 CN CN201811275032.7A patent/CN110054690B/zh active Active
- 2012-11-16 CA CA2856141A patent/CA2856141C/en active Active
- 2012-11-16 ES ES12193121.6T patent/ES2494191T3/es active Active
- 2012-11-16 PT PT121931216T patent/PT2594588E/pt unknown
- 2012-11-16 KR KR1020147015835A patent/KR102047443B1/ko active IP Right Grant
- 2012-11-16 EP EP12193121.6A patent/EP2594588B1/en active Active
- 2012-11-16 MX MX2014005996A patent/MX355482B/es active IP Right Grant
- 2012-11-16 CN CN201280066575.2A patent/CN104144948B/zh active Active
- 2012-11-16 KR KR1020197027994A patent/KR102176469B1/ko active IP Right Grant
- 2012-11-16 DK DK12193121.6T patent/DK2594588T3/da active
- 2012-11-16 JP JP2014541696A patent/JP6321545B2/ja active Active
- 2012-11-16 WO PCT/EP2012/072931 patent/WO2013072512A1/en active Application Filing
- 2012-11-16 CN CN202410037251.0A patent/CN118105479A/zh active Pending
- 2012-11-16 CN CN202111048028.9A patent/CN114044824A/zh active Pending
- 2012-11-16 KR KR1020207029323A patent/KR102249078B1/ko active IP Right Grant
-
2014
- 2014-05-14 IL IL232635A patent/IL232635B/en active IP Right Grant
- 2014-05-15 ZA ZA2014/03548A patent/ZA201403548B/en unknown
-
2015
- 2015-03-16 HK HK15102663.5A patent/HK1202127A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202127A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy (adm) adm adm ig | |
| IL312711A (en) | Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL | |
| IL229254A0 (en) | Therapeutic antibodies | |
| IL221288A0 (en) | Therapeutic methods using anti-cd200 antibodies | |
| ZA201305979B (en) | Endoparasite control agent | |
| HK1197178A1 (en) | Combination als therapy als | |
| ZA201502595B (en) | Therapeutic methods | |
| PL2723330T3 (pl) | Lek kombinowany zawierający środek naczynioskurczowy | |
| IL271284A (en) | Methods for treating or preventing asthma by administering an antagonist to -il-r4 | |
| GB201206306D0 (en) | Therapeutic apparatus | |
| ZA201308992B (en) | Therapeutic antibodies |